School of Medicine
Showing 201-220 of 262 Results
-
Dr. Janaki Manoja Vinnakota
Affiliate, Medicine - Med/Oncology
Visiting Postdoctoral Scholar, Medicine - Med/OncologyBioJanaki Manoja Vinnakota PhD is a Junior Group Leader in the Department of Hematology, Oncology, and Stem Cell Transplantation at the University Medical Center Freiburg, Germany. She is a visiting post-doctoral scholar at Stanford at CCSR. Dr. Vinnakota’s research provided insights into understanding the pathomechanisms associated with central nervous system (CNS) related toxicities such as graft versus host diseases (CNS-GVHD), neurological immune related adverse events (nirAEs) and immune cell associated neurotoxicity syndrome (ICANS) and has most importantly unveiled therapeutic targets with high translational value. She identified the critical role of microglia/myeloid cells in mediating the neurotoxicity and cognitive impairment post diverse cancer immunotherapies. Her work on microglial Syk activation post immune checkpoint inhibition led to a translational application of the most promising and clinically available Syk inhibitor to target CNS irAEs. Dr. Vinnakota was awarded the highly competitive Hans A Krebs Medical Scientist grant, Germany to develop novel therapies that target CAR T cell associated toxicities.
Dr. Vinnakota holds a bachelor's and master's degree in engineering with a focus on biotechnology from IIT Madras, India. Her strong foundation in basic biology has enabled her to investigate projects with significant translational potential. For her Ph.D., Dr. Vinnakota studied the mechanisms of neurotoxicity following allogeneic stem cell transplantation and CAR T cell therapy. During her postdoctoral research, she expanded her expertise to explore neurotoxicity’s associated with immune checkpoint inhibition (anti-PD-1), the gut-microbiome axis in CNS-GVHD, and novel Kinase inhibition strategies to address GVHD.
Dr. Vinnakota was also honored with the prestigious Jan van Rood award from the EBMT society for her work on Targeting ICANS after CD19 CAR T cell therapy and she received the Prize for Innovative Research Approaches in Oncology by the Mertesmann Foundation, Germany for her groundbreaking work on the mechanisms of ICANS after CD19 CAR T cell therapy. Her contributions to immuno-oncology have been published in leading journals such as Nature Cancer, Science Translational Medicine, Journal of Clinical Investigation, and Nature Communications. Additionally, she actively mentors PhD an d MD students working on diverse cancer immunotherapy projects. -
Mrigender Singh Virk
Clinical Associate Professor, Pathology
BioDr. Mrigender Virk completed his residency in Anatomic & Clinical Pathology at Georgetown University before joining Stanford for his Transfusion Medicine Fellowship. After completion of the fellowship, Dr. Virk joined the Department of Pathology as a Clinical Assistant Professor for Transfusion Medicine.
-
Daniel Virtheim
Clinical Research Coordinator, Psych/General Psychiatry and Psychology (Adult)
Current Role at StanfordClinical Research Coordinator
-
Elisa Mariel Visher
Postdoctoral Scholar, Genetics
Current Research and Scholarly InterestsElisa Visher is broadly interested in the (co)evolution of life history strategies, niche breadth, diversification, and adaptability. They use mostly experimental evolution methods in microbial systems to test the predictions and assumptions of theoretical literature. Currently, they am especially interested in understanding the genetics of trade-offs in microbes to better understand patterns of diversity in nature and constraints to adaptation.
-
Brendan C. Visser, MD
Professor of Surgery (General Surgery)
Current Research and Scholarly InterestsDr. Visser's research interests span the breath of his clinical practice. Areas of active research include the multidisciplinary treatment of pancreatic neuroendocrine cancers, technical aspects of minimally invasive pancreatic and liver surgery, and trends in the management of hepatobiliary cancers in California, focusing on socioeconomic and instituional barriers to appropriate care.
-
Lucas Kas Vitzthum, MD
Clinical Associate Professor, Radiation Oncology - Radiation Therapy
BioDr. Vitzthum is a radiation oncologist and clinical associate professor of radiation oncology at Stanford University School of Medicine. He specializes in the treatment of gastrointestinal and thoracic cancers. He also has a clinical and research interest in oligometastatic cancer, which is cancer that has metastasized to a limited number of sites beyond its origin.
He began his career in biomedical engineering and is passionate about integrating new technologies to advance patient care.
Dr. Vitzthum delivers treatment personalized to each patient’s condition, overall health, and goals. He believes clear communication between doctor and patient is vital to help patients make informed care decisions.
His research interests include clinical trial development, survivorship, and predictive modeling to personalize patient treatment. He is especially interested in pursuing research that can address unmet clinical needs.
Dr. Vitzthum has received research support through the Radiological Society of North America, the American Society of Clinical Oncology’s Conquer Cancer Foundation, and the UCSD Altman Clinical and Translational Research Institute. His work has appeared in International Journal of Radiation Oncology Biology Physics, Annals of Oncology, JAMA Oncology, Clinical Cancer Research, and other publications.
He is a member of the American College of Radiation Oncology, American Society for Radiation Oncology, American Society of Clinical Oncology, and Radiologic Society of North America.
Dr. Vitzthum is also interested in improving access to high-quality cancer care for under-served populations domestically and abroad.
